SCOPUS 정보 검색 플랫폼

Clinical Trials

Volumn 4, Issue 2, 2007, Pages 113-124

Simultaneously optimizing dose and schedule of a new cytotoxic agent

(4) Braun, Thomas M a Thall, Peter F b Nguyen, Hoang b De Lima, Marcos b

a UNIVERSITY OF MICHIGAN (United States)

b UNIVERSITY OF TEXAS (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTOTOXIC AGENT;

ARTICLE; BAYES THEOREM; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BRAIN TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; HUMAN; LEUKEMIA; LUNG TOXICITY; MEDICAL PRACTICE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS, PHASE I; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MAXIMUM TOLERATED DOSE; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS;

EID: 34249289754 PISSN: 17407745 EISSN: 17407753 Source Type: Journal
DOI: 10.1177/1740774507076934 Document Type: Article

Times cited : (56)

References (9)

1
- 0024452804
- Design and analysis of phase I clinical trials
- Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925-37.
- (1989) Biometrics , vol.45 , pp. 925-937
- Storer, B.E.¹

2
- 0029027770
- Some pratical improvements in the continual reassessment method for phase I studies
- Goodman S, Zahurak M, Piantadosi, S. Some pratical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14: 1149-61.
- (1995) Stat Med , vol.14 , pp. 1149-1161
- Goodman, S.¹ Zahurak, M.² Piantadosi, S.³

3
- 0031920799
- Cancer phase I clinical trials: Efficient dose escalation with overdose control
- Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998; 17: 1103-20.
- (1998) Stat Med , vol.17 , pp. 1103-1120
- Babb, J.¹ Rogatko, A.² Zacks, S.³

4
- 20744450408
- Determining a maximum tolerated schedule of a cytotoxic agent
- Braun TM, Yuan Z, Thall PF. Determining a maximum tolerated schedule of a cytotoxic agent. Biometrics 2005; 61: 335-43.
- (2005) Biometrics , vol.61 , pp. 335-343
- Braun, T.M.¹ Yuan, Z.² Thall, P.F.³

5
- 16544395591
- DNA methylation and cancer
- Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-42.
- (2004) J Clin Oncol , vol.22 , pp. 4632-4642
- Das, P.M.¹ Singal, R.²

6
- 0004012196
- 2nd edition. Chapman and Hall/CRC
- Gelman A, Carlin JB, Stern HS et al. Bayesian data analysis, 2nd edition. Chapman and Hall/CRC, 2004.
- (2004) Bayesian data analysis
- Gelman, A.¹ Carlin, J.B.² Stern, H.S.³

7
- 0007268978
- Bayesian estimation of item response curves
- Tsutakawa RK, Lin HY. Bayesian estimation of item response curves. Psychometrika 1986; 51: 251-67.
- (1986) Psychometrika , vol.51 , pp. 251-267
- Tsutakawa, R.K.¹ Lin, H.Y.²

8
- 4444272419
- Dose-finding based on efficacy-toxicity trade-offs
- Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004; 60: 684-93.
- (2004) Biometrics , vol.60 , pp. 684-693
- Thall, P.F.¹ Cook, J.D.²

9
- 0025148278
- Continual reassessment method: A practial design for phase I clinical trials in cancer
- O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practial design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
- (1990) Biometrics , vol.46 , pp. 33-48
- O'Quigley, J.¹ Pepe, M.² Fisher, L.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.